NASDAQ:QNTM Quantum Biopharma Earnings Date & Estimates $2.94 -0.17 (-5.47%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$2.98 +0.04 (+1.33%) As of 10/9/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Quantum Biopharma is expected to report earnings on Friday, November 6, 2026. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement Announcement DateNovember 6, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Quantum BiopharmaQuantum Biopharma is expected to post earnings of -$0.50 per share. In the same quarter a year earlier Quantum Biopharma reported -$1.25 per share. Quantum Biopharma last reported on August 13, 2026, posting -$0.47 per share and missing the -$0.4116 consensus estimate. Quantum Biopharma has beaten the consensus EPS estimate in 0 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.50Prior-Year EPS-$1.25Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.47 (Missed by -$0.0584)EPS Beat Rate0 of last 8 quartersPrepare for the Earnings CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ4 2025 Earnings ReportQ3 2025 Earnings Report Quantum Biopharma Earnings FAQ When does Quantum Biopharma report earnings? Quantum Biopharma (NASDAQ:QNTM) is estimated to report earnings on Friday, November 6, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Quantum Biopharma? Analysts expect Quantum Biopharma to post earnings of -$0.50 per share for the quarter. Quantum Biopharma Earnings HeadlinesWorld Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market ...October 8 at 9:30 PM | markets.businessinsider.comWorld Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma SharesOctober 8 at 8:00 AM | globenewswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 10 at 1:00 AM | Banyan Hill Publishing (Ad)Quantum BioPharma (NASDAQ: QNTM) Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS TrialOctober 8 at 6:28 AM | usatoday.comQuantum BioPharma (NASDAQ: QNTM) signs Thermo Fisher contract for Phase 2 Lucid-MSOctober 8 at 2:03 AM | americanbankingnews.comQuantum BioPharma (QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 TrialOctober 7 at 12:57 PM | finance.yahoo.comSee More Quantum Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum Biopharma and other key companies, straight to your email. Email Address About Quantum BiopharmaQuantum Biopharma (NASDAQ:QNTM) (NASDAQ:QNTM) is a biotechnology company focused on developing treatments for neurodegenerative and inflammatory disorders, as well as alcohol and substance-use disorders. The company’s research programs are intended to address conditions for which existing treatment options may be limited. Its lead development program is Lucid-MS, an investigational small-molecule therapy designed to protect or restore myelin, the insulating material surrounding nerve fibers. Quantum BioPharma has identified multiple sclerosis as a potential application for the program and continues to evaluate its broader potential in neurodegenerative diseases. The company also has research activities related to alcohol-use disorder and other central nervous system conditions. Quantum BioPharma was formerly known as FSD Pharma Inc. and adopted its current name as part of a corporate rebranding. The company is based in Canada and conducts its business through research and development activities and related subsidiaries, including Lucid Psycheceuticals. Zeeshan Saeed serves as the company’s chief executive officer and president.View Quantum Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
